DEFA14A: ATAI & Beckley Psytech Report Strong BPL-003 Phase 2a Data

ATAI Life Sciences and Beckley Psytech announced positive Phase 2a clinical trial results for BPL-003, showing improved and sustained antidepressant effects with a two-dose regimen in treatment-resistant depression patients.

Summary

• Positive Phase 2a data for BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD) using a two-dose induction regimen.
• The open-label study involved 12 per-protocol patients receiving an 8 mg dose, followed by a 12 mg dose two weeks later.
• Patients experienced a mean MADRS reduction of 13.3 points from baseline at Day 2 and 12.9 points at Day 8 after the first dose.
• One week after the second dose, the total MADRS reduction from baseline was 19.0 points, with sustained effects of 13.7 points at Week 12.
• Remitter rates increased from 25% one week after the first dose to 50% at Week 8 (6 weeks after the second dose) and 42% at Week 12.
• BPL-003 was generally well-tolerated, with all adverse events classified as mild to moderate and no severe or serious drug-related adverse events.
• Practical administration was confirmed as patients met discharge readiness criteria within two hours after both doses, suggesting ease of integration into psychiatric treatment.
• These findings will inform the design of the Phase 3 clinical program for BPL-003.

Sentiment

Score: 9

Explanation: The filing reports strong positive Phase 2a clinical trial data for BPL-003, demonstrating rapid, durable, and enhanced antidepressant effects with a two-dose regimen, alongside a favorable safety profile and practical administration. This significantly de-risks the program and provides a strong foundation for Phase 3, indicating substantial progress towards addressing a high unmet medical need in TRD. The upcoming Phase 2b OLE data and planned FDA discussions further contribute to a highly positive outlook.

Positives

• Rapid and durable antidepressant effects observed, with a mean MADRS reduction of 13.3 points at Day 2 and 19.0 points one week after the second dose.
• Sustained antidepressant effects were maintained through Week 12, with a 13.7-point reduction from baseline.
• The two-dose regimen significantly improved response and remission rates, with remitter rates doubling from 25% after the first dose to 50% at Week 8.
• BPL-003 demonstrated a strong and consistent tolerability profile, with all adverse events classified as mild to moderate and no severe or serious drug-related adverse events.
• Practical administration was confirmed as patients met discharge readiness criteria within two hours after both doses, suggesting potential for BPL-003 to be integrated into the established interventional psychiatric treatment paradigm.
• The results are consistent with positive topline findings from Beckley Psytech's Phase 2b study of BPL-003 reported in July.

Risks

• The proposed acquisition of Beckley Psytech by atai Life Sciences may not be completed in a timely manner or at all, including the risk that required shareholder approvals are not obtained.
• Failure to realize the anticipated benefits of the proposed acquisition.
• Any or all conditions to the consummation of the proposed acquisition may not be satisfied or waived.
• The occurrence of any event, change, or circumstance that could lead to the termination of the share purchase agreement.
• The announcement or pendency of the proposed acquisition could affect atai's ability to retain and hire key personnel, or its operating results and business generally.
• Forward-looking statements regarding BPL-003 trials and regulatory discussions involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected.

Future Outlook

ATAI and Beckley Psytech are finalizing plans to engage with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to discuss the design of the Phase 3 clinical trial for BPL-003 in patients with TRD. Pending FDA feedback, initiation of Phase 3 trials are expected in the first half of 2026. Additionally, data from the open-label extension of the Phase 2b study is expected in October. The all-share transaction for the combination of atai Life Sciences and Beckley Psytech is expected to close in the second half of 2025.

Management Comments

• "These results underline BPL-003s potential to offer a rapid, well-tolerated and durable treatment option for patients with treatment-resistant depression. They suggest that a second dose of BPL-003 not only maintains, but potentially deepens, antidepressant effects while remaining well-tolerated." Cosmo Feilding Mellen, CEO and Co-Founder of Beckley Psytech.
• "This proof-of-concept study provides compelling evidence that a two-dose induction regimen for BPL-003 may optimize outcomes for patients with treatment-resistant depression. This dosing approach could be further explored in Phase 3 studies, subject to discussions with regulators." Srinivas Rao, CEO and Co-Founder of atai Life Sciences.

Industry Context

This announcement reinforces the growing potential of psychedelic-based therapies for mental health conditions, particularly treatment-resistant depression, which represents a significant unmet medical need affecting millions globally. The positive data for BPL-003 positions atai and Beckley Psytech as leaders in developing rapid-acting, durable, and well-tolerated treatment options within the interventional psychiatry paradigm, aligning with a broader industry trend towards novel approaches beyond traditional antidepressants.

Comparison to Industry Standards

• The results for BPL-003 demonstrate rapid and durable antidepressant effects, which is a key differentiator in the TRD treatment landscape where many existing therapies may have slower onset or require continuous administration.
• The observed MADRS score reductions and remission rates, particularly the doubling of remitter rates to 50% at Week 8, suggest a strong clinical profile compared to the often limited efficacy of conventional antidepressants in TRD patients.
• The short discharge readiness time of two hours after dosing for BPL-003 is a practical advantage, potentially making it more scalable and easier to integrate into healthcare systems than other psychedelic-assisted therapies that may require longer in-clinic monitoring.
• The consistent tolerability profile with only mild to moderate adverse events is favorable, especially when compared to some existing TRD treatments that may have more severe side effects or safety concerns.

Stakeholder Impact

• Shareholders: Positive clinical data for BPL-003 could increase investor confidence and potentially lead to share price appreciation for atai Life Sciences, especially given the significant market for TRD treatments. The successful progression to Phase 3 and the anticipated acquisition closing are key value drivers.
• Patients with TRD: The positive results suggest a promising new rapid-acting, durable, and well-tolerated treatment option for a condition with high unmet medical need, potentially transforming patient outcomes.
• Healthcare Systems: The practical administration and short discharge readiness time of BPL-003 could facilitate easier integration into existing interventional psychiatric treatment paradigms, potentially reducing the burden on healthcare resources compared to more intensive therapies.
• Employees: The positive clinical progress and the impending acquisition could foster a sense of stability and growth opportunities within both atai Life Sciences and Beckley Psytech.

Next Steps

• Data readout from the open-label extension (OLE) of the Phase 2b study of BPL-003 in October.
• Finalizing plans to engage with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to discuss the design of the Phase 3 clinical trial for BPL-003.
• Initiation of Phase 3 trials for BPL-003 expected in the first half of 2026, pending FDA feedback.
• Expected closing of the all-share transaction for the combination of atai Life Sciences and Beckley Psytech in the second half of 2025.

Key Dates

Recommendation

The positive Phase 2a data for BPL-003, demonstrating rapid, durable, and enhanced antidepressant effects with a two-dose regimen, significantly de-risks the clinical program and strengthens the commercial potential for a treatment addressing the substantial unmet need in treatment-resistant depression. The favorable safety profile and practical administration further enhance its market viability. With Phase 3 trials expected to initiate in H1 2026 and the Beckley Psytech acquisition nearing completion, atai is well-positioned to capitalize on this promising asset. This strong clinical progress, combined with strategic corporate development, presents a compelling investment opportunity.

Keywords

ATAI Life Sciences, Beckley Psytech, BPL-003, Treatment-Resistant Depression, TRD, Phase 2a, Clinical Trial, Psychedelic Therapy, Mebufotenin Benzoate, Mental Health, Drug Development, FDA, Biopharmaceutical